NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Price Target & More

$6.65 -0.10 (-1.48 %)
(As of 04/22/2018 08:10 AM ET)
Previous Close$6.65
Today's Range$6.60 - $6.80
52-Week Range$5.30 - $9.95
Volume280,845 shs
Average Volume572,459 shs
Market Capitalization$379.98 million
P/E Ratio-10.23
Dividend YieldN/A
Beta2.23

About Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals logoCorbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. The company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Corbus Pharmaceuticals Holdings, Inc. was founded in 2009 and is based in Norwood, Massachusetts.

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio7.99%
Quick Ratio7.99%

Price-To-Earnings

Trailing P/E Ratio-10.23
Forward P/E Ratio-8.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.44 million
Price / Sales155.73
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book6.39

Profitability

EPS (Most Recent Fiscal Year)($0.65)
Net Income$-32,420,000.00
Net Margins-1,040.41%
Return on Equity-75.88%
Return on Assets-64.67%

Miscellaneous

Employees47
Outstanding Shares57,140,000

How to Become a New Pot Stock Millionaire

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals (NASDAQ:CRBP) announced its earnings results on Monday, March, 12th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.05. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 75.88%. View Corbus Pharmaceuticals' Earnings History.

What price target have analysts set for CRBP?

3 analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $25.3333 in the next twelve months. View Analyst Ratings for Corbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Dr. Yuval Cohen, CEO & Director (Age 43)
  • Dr. Mark A. Tepper Ph.D., Co-Founder, Pres & Chief Scientific Officer (Age 61)
  • Dr. Barbara White M.D., Chief Medical Officer (Age 68)
  • Mr. Sean F. Moran CPA, MBA, CFO & Principal Accounting Officer (Age 60)
  • Scott Constantine M.S., Director of Clinical Research & Operations

Has Corbus Pharmaceuticals been receiving favorable news coverage?

Headlines about CRBP stock have been trending somewhat positive on Sunday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.49 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $6.65.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $379.98 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (CRBP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Corbus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 280.95%. The high price target for CRBP is $32.00 and the low price target for CRBP is $20.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.3333$25.75$24.75$19.75
Price Target Upside: 280.95% upside278.68% upside211.32% upside178.17% upside

Corbus Pharmaceuticals (NASDAQ:CRBP) Consensus Price Target History

Price Target History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2018Noble FinancialReiterated RatingBuyMediumView Rating Details
3/12/2018Cantor FitzgeraldSet Price TargetBuy$32.00LowView Rating Details
1/19/2018Raymond JamesInitiated CoverageOutperform -> Outperform$24.00HighView Rating Details
4/3/2017JMP SecuritiesReiterated RatingOutperform$20.00 -> $27.00LowView Rating Details
11/30/2016AegisReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings History and Estimates Chart

Earnings by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-1.07 EPS

Corbus Pharmaceuticals (NASDAQ CRBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.1550)($0.20)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.16)($0.14)$0.80 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.15)$0.50 million$0.35 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.16)($0.16)$2.50 million$1.29 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.1220)($0.18)$1.50 million$0.38 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.10)($0.12)$1.00 million$0.74 millionViewN/AView Earnings Details
8/15/2016Q216($0.08)($0.11)$1.25 million$0.40 millionViewN/AView Earnings Details
5/16/2016Q116($0.08)($0.08)$0.40 millionViewN/AView Earnings Details
3/29/2016Q4 2015($0.06)($0.06)$1.25 million$0.36 millionViewN/AView Earnings Details
11/10/2015Q315($0.08)($0.06)$0.17 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.06)($0.10)$0.11 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.05)($0.06)ViewN/AView Earnings Details
2/10/2015Q4 2014($0.03)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Corbus Pharmaceuticals (NASDAQ:CRBP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.90%
Institutional Ownership Percentage: 37.01%
Insider Trading History for Corbus Pharmaceuticals (NASDAQ:CRBP)
Insider Trading History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ CRBP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2018Barbara WhiteInsiderBuy2,885$6.89$19,877.65176,935View SEC Filing  
3/14/2018David P HochmanDirectorBuy5,000$6.67$33,350.00459,500View SEC Filing  
3/14/2018Sean F MoranCFOBuy3,100$6.60$20,460.00344,010View SEC Filing  
3/14/2018Yuval CohenCEOBuy1,160$6.89$7,992.4059,935View SEC Filing  
11/15/2017David P HochmanDirectorBuy5,000$6.55$32,750.00459,500View SEC Filing  
11/13/2017David P HochmanDirectorBuy5,000$6.90$34,500.00View SEC Filing  
11/10/2017Barbara WhiteInsiderBuy2,836$7.00$19,852.00174,050View SEC Filing  
11/10/2017David P HochmanDirectorBuy10,000$7.08$70,800.00459,500View SEC Filing  
11/10/2017Sean F MoranCFOBuy1,500$7.04$10,560.00340,910View SEC Filing  
11/10/2017Yuval CohenCEOBuy1,000$7.17$7,170.0058,775View SEC Filing  
8/11/2017Barbara WhiteInsiderBuy2,479$6.05$14,997.95171,214View SEC Filing  
8/11/2017Sean F MoranCFOBuy2,500$5.91$14,775.00339,410View SEC Filing  
8/11/2017Yuval CohenCEOBuy1,695$6.00$10,170.0057,775View SEC Filing  
5/11/2017Barbara WhiteInsiderBuy2,435$6.12$14,902.20168,735View SEC Filing  
5/11/2017David P HochmanDirectorBuy3,400$6.18$21,012.00459,500View SEC Filing  
5/11/2017Sean F MoranCFOBuy3,300$6.14$20,262.00336,910View SEC Filing  
5/11/2017Yuval CohenCEOBuy3,250$6.01$19,532.5056,080View SEC Filing  
3/17/2017Barbara WhiteInsiderBuy4,233$9.49$40,171.17166,300View SEC Filing  
3/13/2017Sean F MoranCFOBuy2,000$9.60$19,200.00333,610View SEC Filing  
12/2/2016Sean F MoranCFOBuy1,500$7.20$10,800.00331,610View SEC Filing  
11/22/2016Alan F HolmerDirectorBuy1,000$7.49$7,490.0022,000View SEC Filing  
11/22/2016Yuval CohenCEOBuy1,340$7.64$10,237.6012,830View SEC Filing  
11/18/2016David P HochmanDirectorBuy10,000$7.00$70,000.00456,100View SEC Filing  
9/8/2016Sean F MoranCFOBuy30,800$5.12$157,696.00330,110View SEC Filing  
8/26/2016Sean F MoranCFOBuy17,900$3.92$70,168.00299,310View SEC Filing  
8/22/2016David P HochmanDirectorBuy1,800$3.77$6,786.00456,100View SEC Filing  
8/18/2016Sean F MoranCFOBuy148,960$3.32$494,547.20216,410View SEC Filing  
8/17/2016Barbara WhiteInsiderBuy38,000$3.15$119,700.00161,067View SEC Filing  
6/8/2016Barbara WhiteInsiderBuy1,935$3.10$5,998.50123,067View SEC Filing  
6/6/2016Yuval CohenCEOBuy1,500$3.34$5,010.0011,490View SEC Filing  
6/1/2016Barbara WhiteInsiderBuy2,570$3.52$9,046.40121,132View SEC Filing  
5/19/2016Sean F MoranCFOBuy27,250$2.37$64,582.50132,450View SEC Filing  
5/18/2016Sean F MoranCFOBuy30,000$2.39$71,700.00105,250View SEC Filing  
5/18/2016Yuval CohenCEOBuy2,125$2.40$5,100.009,990View SEC Filing  
12/11/2015Sean F MoranCFOBuy1,000$1.56$1,560.0075,250View SEC Filing  
12/10/2015Sean F MoranCFOBuy1,000$1.61$1,610.0074,250View SEC Filing  
12/9/2015Sean F MoranCFOBuy1,000$1.67$1,670.0073,250View SEC Filing  
12/8/2015Sean F MoranCFOBuy1,000$1.68$1,680.0072,250View SEC Filing  
12/7/2015Sean F MoranCFOBuy1,000$1.69$1,690.0071,250View SEC Filing  
12/4/2015Sean F MoranCFOBuy1,000$1.72$1,720.0070,250View SEC Filing  
12/2/2015Sean F MoranCFOBuy1,000$1.79$1,790.0069,250View SEC Filing  
11/24/2015Sean F MoranCFOBuy1,500$1.78$2,670.0068,250View SEC Filing  
11/20/2015Sean F MoranCFOBuy1,500$1.70$2,550.0066,750View SEC Filing  
11/19/2015Barbara WhiteInsiderBuy4,000$1.67$6,680.00118,562View SEC Filing  
11/18/2015Sean F MoranCFOBuy1,500$1.71$2,565.0065,250View SEC Filing  
11/17/2015Sean F MoranCFOBuy1,500$1.72$2,580.0063,750View SEC Filing  
11/16/2015Sean F MoranCFOBuy2,000$1.69$3,380.0062,250View SEC Filing  
9/16/2015Sean F MoranCFOBuy5,000$2.12$10,600.0060,250View SEC Filing  
9/15/2015Sean F MoranCFOBuy5,000$2.14$10,700.0055,250View SEC Filing  
9/14/2015Sean F MoranCFOBuy5,000$1.96$9,800.0050,250View SEC Filing  
9/11/2015Sean F MoranCFOBuy5,000$1.85$9,250.0045,250View SEC Filing  
9/3/2015Barbara WhiteInsiderBuy10,000$1.84$18,400.00113,862View SEC Filing  
8/25/2015Barbara WhiteInsiderBuy6,000$1.87$11,220.00103,862View SEC Filing  
8/21/2015Barbara WhiteInsiderBuy10,000$2.05$20,500.0097,862View SEC Filing  
8/21/2015Sean F MoranCFOBuy1,400$2.06$2,884.0040,250View SEC Filing  
8/19/2015Sumner BursteinMajor ShareholderSell200,000$3.04$608,000.003,594,846View SEC Filing  
8/18/2015Barbara WhiteinsiderBuy20,000$1.90$38,000.0087,862View SEC Filing  
8/18/2015Renu GuptaDirectorBuy10,000$1.89$18,900.0015,000View SEC Filing  
8/18/2015Sean F MoranCFOBuy1,000$1.92$1,920.0038,850View SEC Filing  
8/17/2015Avery W CatlinDirectorBuy11,788$1.94$22,868.72View SEC Filing  
8/17/2015Yuval CohenCEOBuy2,100$1.92$4,032.00View SEC Filing  
7/15/2015Sumner BursteinMajor ShareholderSell30,000$2.82$84,600.00View SEC Filing  
6/15/2015Barbara WhiteInsiderBuy2,250$3.25$7,312.50View SEC Filing  
6/12/2015Barbara WhiteInsiderBuy6,000$3.00$18,000.00View SEC Filing  
6/9/2015Avery W CatlinDirectorBuy20,000$3.10$62,000.00View SEC Filing  
6/9/2015Sean F MoranCFOBuy6,500$3.00$19,500.00View SEC Filing  
12/18/2014Sean F MoranCFOBuy18,800$3.36$63,168.00View SEC Filing  
12/17/2014Sean F MoranCFOBuy2,850$3.46$9,861.00View SEC Filing  
12/11/2014Sean F MoranCFOBuy1,000$3.98$3,980.00View SEC Filing  
12/9/2014Sean F MoranCFOBuy1,700$3.98$6,766.00View SEC Filing  
12/4/2014Barbara WhiteInsiderBuy3,300$3.00$9,900.00View SEC Filing  
12/4/2014David P HochmanDirectorBuy1,300$3.05$3,965.00View SEC Filing  
12/4/2014Sean F MoranCFOBuy2,000$3.20$6,400.00View SEC Filing  
12/3/2014Yuval CohenCEOBuy1,000$3.20$3,200.00View SEC Filing  
12/2/2014Sean F MoranCFOBuy1,000$3.03$3,030.00View SEC Filing  
12/1/2014Barbara WhiteInsiderBuy16,448$3.00$49,344.00View SEC Filing  
11/28/2014Barbara WhiteInsiderBuy19,933$3.00$59,799.00View SEC Filing  
11/26/2014Barbara WhiteInsiderBuy13,400$3.00$40,200.00View SEC Filing  
11/26/2014Sean F MoranCFOBuy1,000$3.05$3,050.00View SEC Filing  
11/25/2014Mark TepperInsiderBuy2,000$3.05$6,100.00View SEC Filing  
11/25/2014Sean F MoranCFOBuy3,000$3.05$9,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corbus Pharmaceuticals (NASDAQ CRBP) News Headlines

Source:
DateHeadline
3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?
finance.yahoo.com - April 1 at 10:17 AM
Corbus Pharmaceuticals (CRBP) PT Raised to $20.00Corbus Pharmaceuticals (CRBP) PT Raised to $20.00
www.americanbankingnews.com - April 1 at 9:40 AM
TESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial ReviewTESARO (TSRO) and Corbus Pharmaceuticals (CRBP) Financial Review
www.americanbankingnews.com - March 19 at 2:08 PM
Corbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald AnalystsCorbus Pharmaceuticals (CRBP) Given a $32.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 18 at 12:27 PM
Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to "Sell"Corbus Pharmaceuticals (CRBP) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 17 at 6:44 PM
FY2018 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Cut by Cantor Fitzgerald (CRBP)FY2018 EPS Estimates for Corbus Pharmaceuticals Holdings Inc Cut by Cantor Fitzgerald (CRBP)
www.americanbankingnews.com - March 16 at 10:48 AM
Corbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowCorbus Pharmaceuticals (CRBP) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 3:55 PM
Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Buys 2,885 SharesCorbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Buys 2,885 Shares
www.americanbankingnews.com - March 15 at 1:20 PM
Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Acquires 5,000 Shares of StockInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - March 15 at 1:20 PM
Noble Financial Reaffirms "Buy" Rating for Corbus Pharmaceuticals (CRBP)Noble Financial Reaffirms "Buy" Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - March 14 at 7:16 PM
Insider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Purchases 3,100 Shares of StockInsider Buying: Corbus Pharmaceuticals Holdings Inc (CRBP) CFO Purchases 3,100 Shares of Stock
www.americanbankingnews.com - March 14 at 1:35 PM
Corbus Wounded in FY17, Shares SinkCorbus Wounded in FY17, Shares Sink
www.baystreet.ca - March 13 at 11:45 AM
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical UpdateCorbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
finance.yahoo.com - March 13 at 11:45 AM
Corbus Pharmaceuticals (CRBP) Issues  Earnings ResultsCorbus Pharmaceuticals (CRBP) Issues Earnings Results
www.americanbankingnews.com - March 13 at 11:12 AM
Corbus Pharmaceuticals Holdings Inc (CRBP) Receives Average Recommendation of "Buy" from BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 9:37 AM
Corbus Pharmaceuticals (CRBP) Upgraded to Hold by ValuEngineCorbus Pharmaceuticals (CRBP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - March 4 at 8:56 PM
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care ConferenceCorbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
finance.yahoo.com - March 2 at 10:27 AM
Corbus Pharmaceuticals Holdings Inc (CRBP) Stake Lessened by Raymond James Financial Services Advisors Inc.Corbus Pharmaceuticals Holdings Inc (CRBP) Stake Lessened by Raymond James Financial Services Advisors Inc.
www.americanbankingnews.com - March 2 at 8:21 AM
What Is Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Financial Position?What Is Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) Financial Position?
finance.yahoo.com - February 22 at 10:14 AM
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical ModelCorbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
finance.yahoo.com - February 15 at 3:55 PM
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 14 at 3:21 PM
Corbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings Inc (CRBP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 9:22 AM
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare ConferenceCorbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 3:19 PM
Corbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClubCorbus Pharmaceuticals (CRBP) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 3 at 8:46 PM
Corbus Is A Buy, But Not For Cystic Fibrosis - Seeking AlphaCorbus Is A Buy, But Not For Cystic Fibrosis - Seeking Alpha
seekingalpha.com - February 2 at 5:43 AM
Corbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking AlphaCorbus Pharma awarded $25M from CF Foundation to support development of lenabasum; shares up 3% premarket - Seeking Alpha
seekingalpha.com - February 1 at 3:18 PM
Wired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of LenabasumWired News – Cystic Fibrosis Foundation Gets Development Award to Support Corbus Pharma’s Phase-2b Clinical Study of Lenabasum
finance.yahoo.com - February 1 at 3:18 PM
Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.comCorbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary ... - StreetInsider.com
www.streetinsider.com - January 31 at 5:49 AM
Pre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.comPre-Open Movers 01/30: (SMRT) (CALD) (CRBP) Higher; (SMG) (MXIMI) (ESRX) (UNH) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - BenzingaCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support ... - Benzinga
www.benzinga.com - January 30 at 3:18 PM
Corbus Pharma on go to start mid-stage study of lenabasum in cystic fibrosis; shares up 2% after hours - Seeking AlphaCorbus Pharma on go to start mid-stage study of lenabasum in cystic fibrosis; shares up 2% after hours - Seeking Alpha
seekingalpha.com - January 30 at 3:18 PM
Corbus Pharma (CRBP) Secures $25M Development Award from ... - StreetInsider.comCorbus Pharma (CRBP) Secures $25M Development Award from ... - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of LenabasumCorbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
finance.yahoo.com - January 30 at 3:18 PM
Corbus cystic fibrosis drug to get U.S. FDA review on flare-up dataCorbus cystic fibrosis drug to get U.S. FDA review on flare-up data
www.nasdaq.com - January 30 at 5:46 AM
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary EndpointCorbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
finance.yahoo.com - January 30 at 5:46 AM
Corbus Pharmaceuticals (CRBP) Upgraded by BidaskClub to "Buy"Corbus Pharmaceuticals (CRBP) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 28 at 9:30 AM
4 Drug Stocks to Watch - Nasdaq4 Drug Stocks to Watch - Nasdaq
www.nasdaq.com - January 24 at 3:21 PM
Analysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Ferroglobe, Corbus Pharmaceuticals, Meritage, Dicerna Pharmaceuticals, Castle Brands, and Ply Gem — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - January 24 at 8:31 AM
Why the Medical Marijuana Industry Is GrowingWhy the Medical Marijuana Industry Is Growing
finance.yahoo.com - January 22 at 7:56 AM
Corbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Raymond James FinancialCorbus Pharmaceuticals (CRBP) Coverage Initiated by Analysts at Raymond James Financial
www.americanbankingnews.com - January 20 at 4:08 PM
How Marijuana Acceptance Is Evolving GloballyHow Marijuana Acceptance Is Evolving Globally
finance.yahoo.com - January 19 at 5:46 PM
Cannabis Market Sales on the Rise According to Data - PR Newswire (press release)Cannabis Market Sales on the Rise According to Data - PR Newswire (press release)
www.prnewswire.com - January 10 at 9:38 AM
BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍
www.reuters.com - January 6 at 9:36 AM
Opinion: Harry Boxers four stocks popping to start the new year - MarketWatchOpinion: Harry Boxer's four stocks popping to start the new year - MarketWatch
www.marketwatch.com - January 5 at 5:01 PM
Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)
www.americanbankingnews.com - January 4 at 3:36 AM
Corbus Pharmaceuticals (CRBP) Buy Rating Reiterated at Noble FinancialCorbus Pharmaceuticals' (CRBP) Buy Rating Reiterated at Noble Financial
www.americanbankingnews.com - December 30 at 6:14 AM
Corbus Pharmaceuticals (CRBP) Rating Increased to Hold at BidaskClubCorbus Pharmaceuticals (CRBP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 29 at 11:56 AM
ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 26, 2017ETFs with exposure to Corbus Pharmaceuticals Holdings, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 11:28 AM
Noble Financial Reaffirms Buy Rating for Corbus Pharmaceuticals (CRBP)Noble Financial Reaffirms Buy Rating for Corbus Pharmaceuticals (CRBP)
www.americanbankingnews.com - December 25 at 1:32 PM
Corbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClubCorbus Pharmaceuticals (CRBP) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 24 at 9:20 AM

SEC Filings

Corbus Pharmaceuticals (NASDAQ:CRBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corbus Pharmaceuticals (NASDAQ:CRBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corbus Pharmaceuticals (NASDAQ CRBP) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.